GLP-1 Medications: What Cedar Park Residents Should Know
GLP-1 medications like Ozempic and Wegovy explained by a Cedar Park dietitian. Learn side effects, muscle loss risks, and what to eat for best results.
Hema Cherukooru, RDN, LD
8/19/202612 min read
If you or someone you love has started a GLP-1 medication like Ozempic, Wegovy, Mounjaro, or Zepbound, you probably have questions. These medications are everywhere right now, and the science behind them is genuinely exciting. But like any tool, they work best when you understand how they work, who they are for, and how to support your body while using them.
As a registered dietitian, I get asked about these medications most often. Here is a plain-language breakdown of what the research actually shows, including what to eat to protect your muscle, bones, and overall health while on therapy.
What Are GLP-1 Medications and How Do They Work?
GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut naturally releases after you eat. It helps your body release insulin at the right time, tells your pancreas to slow down glucagon production (which reduces liver glucose production), slows how fast food leaves your stomach, and sends "I'm full" signals to your brain.
The catch is that natural GLP-1 breaks down in your body within minutes. GLP-1 medications are lab-made versions built to last much longer, so those effects (better blood sugar control and a stronger sense of fullness) stick around.
Medications in this category include semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide, and dulaglutide.
Callout: Why does this matter for eating habits? Because these medications change hunger and fullness signals, many people find their appetite and food preferences shift significantly. Research shows daily calorie intake can drop by 24 to 39 percent on semaglutide or tirzepatide. That is a big change, and it is exactly where working with a dietitian helps, so you can protect muscle mass, meet your nutrient needs, and adjust portions in a way that feels sustainable.
Who Are These Medications Typically Recommended For?
Adults with type 2 diabetes, especially those who also have obesity, heart disease, heart failure, or chronic kidney disease
Adults with a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related health condition
Some adolescents age 12 and up with obesity (semaglutide and liraglutide are approved for this age group; tirzepatide is not)
People at higher cardiovascular risk, since large trials have shown these medications can meaningfully lower rates of heart attack, stroke, heart failure hospitalization, and death
People with type 2 diabetes and chronic kidney disease, since research has shown a meaningful drop in major kidney complications
Emerging use in fatty liver disease (MASH), sleep apnea, knee osteoarthritis, and PCOS
Who Should Be Cautious or Avoid These Medications?
Your prescriber will screen for this, but it helps to know what they are checking for.
Should not use:
Personal or family history of medullary thyroid cancer or MEN2 syndrome
Known allergy to the medication
Pregnancy or breastfeeding
Use with caution:
History of pancreatitis
Prior gastric surgery
Severe gastroparesis or bowel obstruction
Significantly elevated triglycerides
Advanced kidney or liver disease
Older adults with unexplained weight loss or low muscle mass
Before starting, a good care team will also check your labs, screen for eating disorders, ask about your mental health, review your other medications (sulfonylureas and insulin often need adjusting), and, for semaglutide especially, confirm you have had a recent eye exam.
What Side Effects Should I Expect?
Callout: The most common side effects are digestive Up to 40 to 50 percent of people experience nausea, vomiting, diarrhea, or constipation, especially while the dose is being increased. These symptoms are usually temporary and often improve with a slower dose increase and some simple food strategies.
Less common side effects include gallbladder issues (research shows about a 37 percent higher risk of biliary disease), a mild increase in heart rate, injection site reactions, hair thinning, fatigue, and headaches.
Rare but important side effects include pancreatitis and, in people with existing diabetic retinopathy, a temporary worsening tied to how quickly blood sugar drops rather than the medication itself.
What Nutrients Should You Prioritize on a GLP-1 Medication?
This is the part of the conversation that matters most for how you feel day to day, and it is where a dietitian adds the most value.
Protein: your top priority
Because appetite drops so much, it becomes easy to lose muscle along with fat. Research shows lean muscle can account for up to 40 percent of total weight lost during GLP-1 therapy, and one review found that formal protein tracking was rarely even done in clinical trials, meaning many people are likely falling short without realizing it.
A 2025 joint advisory from several major nutrition and obesity medicine organizations recommends:
1.2 to 1.6 grams of protein per kilogram of body weight per day during active weight loss
An absolute target of 80 to 120 grams per day for most adults, since this is often easier to track than a per-kilogram number
Never dropping below 0.4 to 0.5 g/kg/day, and not chronically exceeding 2 g/kg/day
For adults 65 and older, aiming closer to 1.2 to 1.5 g/kg/day, since this age group faces higher sarcopenia risk
Because appetite is low, it helps to prioritize protein-dense, low-volume foods: Greek yogurt, cottage cheese, eggs, fish, lean meats, legumes, and, when needed, a fortified protein shake or bar. Eating your protein source first at each meal, before other foods, is a simple strategy that helps you hit your target even with a smaller appetite.
Callout: Protein alone is not enough. Research consistently shows that protein needs to be paired with resistance training to actually preserve muscle. One landmark trial found that exercise combined with a GLP-1 medication preserved lean mass, doubled fat loss compared to either approach alone, and even prevented the mild heart rate increase sometimes seen with these medications. Another review found structured resistance training for 10 or more weeks led to meaningful gains in both muscle mass and strength, even while on therapy.
Fiber and fluids: managing GI side effects
Constipation is common as food moves more slowly through your system. The general approach is to gradually build up fiber (prunes, dried fruit, vegetables, whole grains) while making sure you are drinking enough fluids, generally more than 2 to 3 liters of water per day, since dehydration risk is real with nausea, vomiting, or diarrhea.
A few practical notes:
In the first few days after starting or increasing your dose, a high-fiber diet can sometimes make nausea worse temporarily. Smaller, more frequent meals and a gentler approach to fiber during this window can help.
High-protein, high-fat meals can slow digestion even further and worsen constipation, so balance matters.
If diet alone is not enough, options like magnesium citrate, a fiber supplement, or PEG 3350 (Miralax) can help, ideally in consultation with your care team.
Because dehydration from GI symptoms can lead to more serious problems like acute kidney injury, staying ahead of your fluid intake is a safety issue, not just a comfort issue.
Calcium and vitamin D: supporting bone health
Bone density loss during GLP-1 therapy appears to be driven by the weight loss itself rather than a direct effect of the drug, and tends to be more noticeable in people without diabetes who lose larger amounts of weight.
The reassuring news from recent research in people with type 2 diabetes:
A 2025 review of 25 clinical trials found no increased fracture risk, and actually showed improvements in bone density at the spine and hip
A separate analysis of 26 trials found increases in markers of healthy bone turnover along with improved bone mineral density
As with muscle, exercise appears to be the key protective factor. Trial data shows that GLP-1 therapy paired with exercise preserved bone density, while GLP-1 therapy alone led to a decrease. If you have risk factors for osteoporosis, it is worth asking your provider about checking your calcium and vitamin D status.
Micronutrient screening: don't overlook the basics
When you are eating significantly less food overall, you can end up short on key nutrients even if you are not trying to restrict. This is especially true for iron, potassium, vitamin D, and calcium, particularly in older adults, those with existing health conditions, or anyone losing weight quickly.
GLP-1 medications do not block fat digestion directly, but changes in stomach emptying and bile secretion can still affect how well you absorb certain nutrients, including fat-soluble vitamins. Including healthy fats in your meals (olive oil, avocado, nuts, fatty fish) can help support this absorption. If you are on a GLP-1 medication long term, periodic lab screening for these nutrients is a reasonable conversation to have with your provider.
Do These Medications Work Long Term?
Research following people for one to two and a half years shows real, sustained benefits: fewer cardiovascular events, better blood sugar control, and lower rates of death from heart-related causes.
But here is the part that matters most from a nutrition standpoint: when people stop taking these medications, weight regain is common. The ADA 2026 Standards of Care state that discontinuation of semaglutide and tirzepatide results in recurrence of one-half to two-thirds of the weight lost within 1 year, with reversal of cardiometabolic improvements. Studies on semaglutide and tirzepatide both found that a significant portion of lost weight returns within about a year of stopping. This is one of the reasons researchers now describe obesity as a chronic condition that may need ongoing management, similar to how we approach high blood pressure.
Callout: This is exactly what a dietitian can help you plan. A personalized nutrition plan while on a GLP-1 medication should prioritize protein at every meal, include enough fiber and fluids to manage GI side effects, support bone health with adequate calcium and vitamin D, and make sure you are still getting the vitamins and minerals your body needs even while eating less overall.
Frequently Asked Questions
How much protein do I actually need on a GLP-1 medication? Most adults should aim for 1.2 to 1.6 grams of protein per kilogram of body weight per day, or roughly 80 to 120 grams total for many adults. Adults 65 and older should aim toward the higher end of that range to protect against muscle loss.
Will I lose muscle if I take a GLP-1 medication? Some lean mass loss is common; research shows it can account for up to 40 percent of total weight lost. It is not inevitable in a harmful way, though. Prioritizing protein intake and resistance exercise helps protect muscle while you lose fat.
Do I need to change my diet while on these medications? Yes, most people do. Because appetite drops significantly, it becomes easier to under-eat protein, fiber, and key nutrients. A dietitian can help you build a smaller-volume meal plan that still meets your needs.
How much water should I be drinking? Generally more than 2 to 3 liters per day, since reduced appetite and possible nausea or diarrhea raise your dehydration risk.
Will these medications weaken my bones? Current research in people with type 2 diabetes is reassuring, showing no increased fracture risk and even some improvement in bone density, especially when paired with exercise. Bone loss is more of a concern with larger amounts of weight loss, which is another reason resistance training matters.
What happens if I stop taking the medication? Research shows weight regain is common after stopping, often within the first year. Many people benefit from a long-term plan that includes nutrition and lifestyle strategies whether or not they stay on the medication long term.
Are the nausea and digestive side effects permanent? Usually not. They tend to be most noticeable during dose increases and often ease with time, slower titration, smaller meals, and specific food choices.
Can I take a GLP-1 medication if I have a history of gallstones or pancreatitis? This requires a conversation with your prescriber. Gallbladder disease risk is higher on these medications, and a personal history of pancreatitis generally calls for extra caution.
Work With a Cedar Park Dietitian Who Understands GLP-1 Nutrition
Starting a GLP-1 medication is a big step, and getting the nutrition side right can make all the difference in how you feel and the results you see. At Hita Nutrition, I work with clients throughout Cedar Park, Leander, Round Rock, Georgetown, and the greater Austin area to build practical, protein-focused eating plans that protect muscle and bone, ease digestive side effects, and support long-term success, whether you are just starting out or have been on treatment for months.
If you are on a GLP-1 medication or considering one, reach out to schedule a nutrition consultation. Let's build a plan that works with your medication, not against it.
References
Alexander, J. T., Staab, E. M., Wan, W., Gibbons, R. D., & Laiteerapong, N. (2022). The longer-term benefits and harms of glucagon-like peptide-1 receptor agonists: A systematic review and meta-analysis. Journal of General Internal Medicine, 37(15), 3932–3941. doi.org
American Diabetes Association Professional Practice Committee. (2026a). 8. Obesity and weight management for the prevention and treatment of diabetes: Standards of care in diabetes—2026. Diabetes Care, 49(Suppl 1), S146–S167. doi.org
American Diabetes Association Professional Practice Committee. (2026b). 13. Older adults: Standards of care in diabetes—2026. Diabetes Care, 49(Suppl 1), S244–S266. doi.org
Anastasilakis, A. D., Paccou, J., Palermo, A., & Polyzos, S. A. (2025). The effects of anti-obesity medications on bone metabolism: A critical appraisal. Diabetes, Obesity & Metabolism, 27(2), 289–302. doi.org
Bansal, M. B., Patton, H., Morgan, T. R., Loomba, R., & Charlton, M. R. (2025). Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD practice guidance. Hepatology, 82(5), 1541–1546. doi.org
Blumenthal, J. A., Babyak, M. A., Sherwood, A., Craighead, L., Lin, P. H., Watkins, L. L., ... Hinderliter, A. (2010). Effects of the Dietary Approaches to Stop Hypertension diet alone and in combination with exercise and caloric restriction on insulin sensitivity and lipids. Hypertension, 55(5), 1199–1205. doi.org
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021). SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications. Lancet, 398(10296), 262–276. doi.org
Cowart, K., & Carris, N. W. (2025). Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations? Diabetes, Obesity & Metabolism, 27(1), 12–21. doi.org
Damhof, M. A., van Bruggen, F. H., & van Roon, E. N. (2026). Early weight regain after GLP-1 receptor agonist discontinuation: Mechanisms and implications for treatment de-escalation strategies. Diabetes, Obesity & Metabolism, 28(4), 712–723. doi.org
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Jr., Kazi, D. S., Kosiborod, M. N., ... Sperling, L. S. (2020). 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: A report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology, 76(9), 1117–1145. doi.org
Davies, M. J., Aroda, V. R., Collins, B. S., Kahn, S. E., Mathieu, C., Mindenae, J. J., ... Buse, J. B. (2022). Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 45(11), 2753–2786. doi.org
De Block, C. E. M., Dirinck, E., Verhaegen, A., & Van Gaal, L. F. (2022). Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes. Diabetes, Obesity & Metabolism, 24(12), 2314–2328. doi.org
de Paulo, R. S., Bonifacio, D. B., de Carvalho, M. H. L., & Bressan, J. (2026). Dietary strategies and nutritional management in patients receiving GLP-1 and dual GIP/GLP-1 receptor agonists as adjuncts to lifestyle interventions: A systematic review of randomised clinical trials. Diabetes, Obesity & Metabolism, 28(6), 945–957. doi.org
Food and Drug Administration. (2026). Approved drug products with therapeutic equivalence evaluations (46th ed.). U.S. Department of Health and Human Services.
Galli, M., Benenati, S., Laudani, C., ... Crea, F. (2025). Cardiovascular effects and tolerability of GLP-1 receptor agonists: A systematic review and meta-analysis of 99,599 patients. Journal of the American College of Cardiology, 85(5), 512–527. doi.org
Jensen, S. B. K., Sørensen, V., Sandsdal, R. M., ... Stallknecht, B. (2024). Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: A secondary analysis of a randomized clinical trial. JAMA Network Open, 7(6), e2418514. doi.org
Kunutsor, S. K., & Seidu, S. (2025). Safety and tolerability of glucagon-like peptide-1 receptor agonists: A state-of-the-Art narrative review. Drugs, 85(3), 241–259. doi.org
Kushner, R. F., Chao, A. M., & Wadden, T. A. (2026). Lifestyle modification and incretin-based therapy for obesity. The Journal of the American Medical Association, 335(4), 412–421. doi.org
Lee, M. M. Y., Sattar, N., Pop-Busui, R., ... McMurray, J. J. V. (2025). Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: A systematic review and meta-analysis of randomized trials. Diabetes Care, 48(4), 742–754. doi.org
Li, X., Li, Y., & Lei, C. (2023). Effects of glucagon-like peptide-1 receptor agonists on bone metabolism in type 2 diabetes mellitus: A systematic review and meta-analysis. International Journal of Endocrinology, 2023, Article 6652410. doi.org
Lieberman, D. E., Aslan, D. H., & Heymsfield, S. B. (2026). The conundrum of exercise for weight management in the GLP-1 receptor agonist era. The Journal of the American Medical Association, 335(3), 245–246. doi.org
Locatelli, J. C., Costa, J. G., Haynes, A., ... Green, D. J. (2024). Incretin-based weight loss pharmacotherapy: Can resistance exercise optimize changes in body composition? Diabetes Care, 47(10), 1845–1856. doi.org
Lundgren, J. R., Janus, C., Jensen, S. B. K., ... Torekov, S. S. (2021). Healthy weight loss maintenance with exercise, liraglutide, or both combined. The New England Journal of Medicine, 384(21), 1991–2002. doi.org
Mehrtash, F., Dushay, J., & Manson, J. E. (2025). Integrating diet and physical activity when prescribing GLP-1s—lifestyle factors remain crucial. JAMA Internal Medicine, 185(5), 401–402. doi.org
Mozaffarian, D., Agarwal, M., Aggarwal, M., ... Mechanick, J. I. (2025). Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. The American Journal of Clinical Nutrition, 121(3), 612–629. doi.org
Spreckley, M., Ruggiero, C. F., & Brown, A. (2026). Nutrition strategies for next-generation incretin therapies: A systematic scoping review of the current evidence. Obesity Reviews, 27(5), e13990. doi.org
Tan, Y., Liu, S., & Tang, Q. (2025). Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: A systematic review and meta-analysis. Acta Diabetologica, 62(3), 401–414. doi.org
Vadini, V., Duan, D., & Moseley, K. F. (2026). Impact of GLP-1 receptor agonists on bone metabolism. The Journal of Clinical Endocrinology and Metabolism, 111(4), e412–e425. doi.org
